CELL INTELLIGENCE · 肿瘤细胞治疗研究

CELLIN 肿瘤细胞治疗研究

← 返回

费城染色体阳性成人急性淋巴细胞白血病三线治疗的结果

英文原题：Results of Third-Line Therapy in Philadelphia Chromosome-Positive Adult Acute Lymphoblastic Leukemia.

查看英文原题

Results of Third-Line Therapy in Philadelphia Chromosome-Positive Adult Acute Lymphoblastic Leukemia.

PubMed 2026/06/10（内容时间） Clin Lymphoma Myeloma Leuk Q1 · IF 4.1（JCR 2025）

分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。

人群：成人技术：CAR-T急性淋巴细胞白血病淋巴瘤骨髓瘤地区：美国
登录后收藏与关注 全文解读登录并开通会员后使用加入对比登录并开通会员后使用

研究概要

费城染色体阳性急性淋巴细胞白血病成人患者在接受二线挽救治疗时，若采用过去十年间可用的新策略进行三线治疗，目前已有合理的疗效预期。

研究思路结论见上方概要

背景

费城染色体（Ph）阳性急性淋巴细胞白血病（ALL）成人患者第二次复发接受三线治疗（Salvage 2）的历史结果极差。使用标准化疗的完全缓解率为20%，中位总生存期为2至3个月。随着近期新型治疗策略的出现，包括靶向抗体和工程化CAR-T 细胞疗法，以及更强效的BCR::ABL1酪氨酸激酶抑制剂，这一情况可能正在改变。研究目的：分析Ph阳性ALL成人患者在不同治疗模式下Salvage 2的结局。

方法

共分析了1992年至2025年间接受Salvage 2治疗的89例Ph阳性ALL成人患者。

结果

完全缓解（CR）率为58%；3年生存率为17%。多因素分析显示，对CR和生存最具显著独立有利预测因素的是所采用的治疗类型。在2017年以来接受治疗的27例患者中，CR率为89%，3年生存率为52%。

展开英文摘要原文
BACKGROUND

The historical results in adults with Philadelphia chromosome (Ph)-positive acute lymphoblastic leukemia (ALL) in second relapse treated with third-line therapy (Salvage 2) are extremely poor. Using standard chemotherapy resulted in complete response rates of 20% and a median overall survival of 2 to 3 months. This may be changing with the recent availability of novel therapeutic strategies, including targeted antibodies and engineered chimeric antigen receptor T-cell therapy, as well as more potent BCR::ABL1 tyrosine kinase inhibitors. STUDY AIMS: Analyze the outcome of adults with Ph-positive ALL with different modalities in Salvage 2.

PATIENTS AND METHODS

A total of 89 adults with Ph-positive ALL in Salvage 2 treated from 1992 until 2025 were analyzed.

RESULTS

The complete remission (CR) rate was 58%; the 3-year survival rate was 17%. By multivariate analysis, the most significant independent favorable predictors for CR and survival were the type of therapy utilized. Among 27 patients treated since 2017, the CR rate was 89% and the 3-year survival rate 52%.

CONCLUSIONS

Adults with Ph-positive ALL in Salvage 2 receiving third-line therapy now have reasonable outcome expectations with the newer strategies available in the past decade.

论文信息

作者
Jen WY、Jabbour E、Kugler E、Jain N、Garris R、Short NJ、Pierce S、Khouri I
单位
Department of Leukemia, The University of Texas, MD Anderson Cancer Center, Houston, TX. Electronic address: WJen@mdanderson.org.United States
期刊
Clinical lymphoma, myeloma & leukemia2026 Aug
原文标识
PubMed 42392945　·　DOI 10.1016/j.clml.2026.06.002

在 PubMed 查看 → 出版商原文（DOI） 全文 PDF（PMC）· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →